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Abstract
Background. Patients treated with valproic acid (VPA) present a high incidence of non-alcoholic fatty liver disease (NAFLD)
(around 61%). Several recent studies suggest that low copper stores could be associated with NAFLD, and a signiﬁcant
decrease of copper availability in VPA-treated patients has been described.
Design and methods. In 101 adult epileptic patients treated with valproic acid in monotherapy (n = 75) and polytherapy (n = 26)
the copper availability was evaluated using the speciﬁc oxidase activity of ceruloplasmin (activity per unit mass of enzyme
protein) and the copper/ceruloplasmin ratio. Copper deﬁciency was supposed in the cases in which this biochemical variable
was smaller than the lower reference limit (333 U/g).
Results. The differences between the groups of patients with ceruloplasmin oxidase activity smaller or greater than 333 U/g for
the serum levels of aminotransferases, gamma-glutamyltransferase, butyrylcholinesterase, cholesterol, triglycerides, and
C-reactive protein, and the APRI and FIB-4 liver ﬁbrosis scores were not statistically signiﬁcant. Most patients (93%)
had low APRI and FIB-4 scores, suggesting absence of signiﬁcant liver ﬁbrosis.
Conclusions. The results obtained do not conﬁrm the hypothesis of an association between diminished copper availability and
NAFLD in patients treated with valproic acid.
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Introduction
Valproic acid (VPA) has been widely used since the
late 1960s for the treatment of generalized and partial
seizures, and it is still the antiepileptic drug with the
broadest spectrum (1). New roles for this old drug
were later conﬁrmed, due to its beneﬁcial effects in
bipolar disorders, schizophrenia, depression, neuro-
logical pain, migraine headaches, and a number of
neurodegenerative diseases (2,3).
It has been highlighted that on rare occasions
serious complications may occur in some VPA-
treated patients, including pancreatitis, coagulopa-
thies, induced hepatotoxicity, and encephalopathy,
although there is still a lack of knowledge about
the incidence of these special side effects (1).
Type I VPA-associated hepatotoxicity consists of a
dose-dependent elevation of serum liver enzymes,
which normalize after drug discontinuation, and
type II consists of a rare idiosyncratic VPA-associated
hepatotoxicity that is normally lethal (1).
VPA has a signiﬁcant steatogenic effect in HpG2
cell cultures (4), and development of fatty liver is one
of the clinical ﬁndings during treatment with this drug
(5). Using abdominal ultrasound, Luef et al. demon-
strated that non-alcoholic fatty liver disease was
present in 61% of VPA-treated patients (6), with
this high prevalence being conﬁrmed in a more
recent study (7). Impaired hepatic fatty acid oxida-
tion directly inhibiting mitochondrial b-oxidation
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metabolic pathway, has been proposed as a possible
mechanism for VPA-induced steatosis(4,5,8).
Chronic treatment with enzyme-inducing antiep-
ileptic drugs (carbamazepine, phenobarbital, or phe-
nytoin) does not produce copper deﬁciency (9).
However, the administration of VPA produces a
signiﬁcant increase of copper biliary excretion in
rats (10), and previously published results suggest
that diminished copper availability is substantially
prevalent among epileptic patients treated with VPA
(11). In accordance with Aigner et al., a signiﬁcant
proportion of non-alcoholic fatty liver disease
patients should be considered copper-deﬁcient (12),
and reduced copper availability may be involved in
the development of non-alcoholic fatty liver (13), a
hypothesis put forward at an earlier date by
Geubel et al. (14).
In our study, an investigation was carried out in
epileptic patients treated with VPA on the possible
relationship between copper availability and the
serum activities of several liver enzymes, whose
increase in non-alcoholic fatty liver disease is widely
documented (15–22). As previously reported, copper
deﬁciency was supposed in cases with a smaller
ceruloplasmin-speciﬁc oxidase activity (activity per
mass unit of enzyme protein) than the estimated lower
limit of reference (11).
Patients and methods
A group of 101 epileptic out-patients (56 males and
45 females) with a mean age (±SEM) of 43.7 ±
2.5 years (range 17–84 years) and treated with VPA
in monotherapy (n = 75) or polytherapy with associ-
ated phenytoin, carbamazepine, and phenobarbital
(n = 26) were studied. In all cases the daily drug
administration was carried out in multiple doses. The
blood samples were drawn before the breakfast and
the morning dose of antiepileptic drugs, which had
not been modiﬁed for at least 3 months prior to the
study. Consequently the serum levels of VPA corre-
spond to the trough steady-state concentrations (Css).
None of the patients was receiving a copper dietary
supplement, and pregnant women or those taking oral
contraceptives were excluded. This study was carried
out according to the good practice rules for investi-
gation in humans of the Conselleria de Sanidade
(Regional Ministry of Health) of the Xunta de Galicia,
Spain.
Serum copper concentration was determined by
atomic absorption spectrometry (Perkin Elmer mod
5100PC, Waltham, USA) with carbon red atomiza-
tion. Immunoreactive ceruloplasmin was determined
in a BN ProSpec nephelometer (Siemens Health Care
Diagnostics Inc., Newark, USA). The oxidase activity
of ceruloplasmin was determined as previously
described at 30C using o-dianisidine dihydrochlor-
ide as a substrate (23), and the ceruloplasmin-
speciﬁc oxidase activity was calculated using the
expression: speciﬁc oxidase activity (U/g) = 1000 
oxidase activity (U/L)/immunoreactive ceruloplasmin
(mg/L). Serum VPA concentrations were determined
in a Dimension Xpand analyzer using reagents from
Siemens Health Care Inc. Serum activities of alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), gamma-glutamyltransferase (GGT), alkaline
phosphatase (ALP),and butyrylcholinesterase (ChE),
and concentrations of glucose, cholesterol, and tri-
glycerides, were determined in an Advia 2400 Chem-
istry System (Siemens Health Care Diagnostics Inc.).
The platelet count, mean platelet volume (MPV), and
platelet size distribution width (PDW) were measured
in blood samples collected 2–3 hours beforehand
in K3EDTA anticoagulated tubes using an Advia
2120 Hematology System (Siemens Health Care
Diagnostics Inc.). High-sensitivity C-reactive protein
(CRP) was determined in a BN II nephelometer
(Siemens Health Care Diagnostics Inc.).
The AST-to-platelet ratio index (APRI) was
calculated in accordance with Wai et al. (24):
APRI = (AST:URL/platelet count (10
9/L))  100,
where URL corresponds to the AST upper reference
limits for men and women. The 4-variables liver ﬁbro-
sis index (FIB-4) was calculated in accordance with
Sterling et al. (25): FIB-4 = age  AST/platelets
(10
9/L)  ALT
1/2, where age is expressed in years
and the AST and ALT activities in U/L.
Statistical analysis of data was performed using
the StatGraphics package, and the Kolmogorov-
Smirnov test was applied to check for normality.
Pearson’s correlation coefﬁcient was used when
t h ed a t ah a daG a u s s i a nd i s t r i b u t i o n .O t h e r -
wise, Spearman’s correlation coefﬁcient was used.
The results were expressed as mean ± SEM
(median).
Results
The estimated lower reference limit for the speciﬁc
oxidase activity of ceruloplasmin (2.5 percentile of
the control group) was 333 U/g (11). Table I shows
the results obtained for the different biochem-
ical variables assayed in the patients treated with
VPA in monotherapy, grouped according to their
ceruloplasmin-speciﬁc oxidase activities (smaller or
greater than 333 U/g). The differences between
the mean (median) were not statistically signiﬁcant,
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copper/immunoreactive ceruloplasmin ratio, which
was signiﬁcantly lower in the group of patients with
ceruloplasmin-speciﬁc oxidase activities <333 U/g.
Analogousresultswereobtainedforthepatientstreated
with VPA in polytherapy (Table II). In both cases,
signiﬁcant differences were not achieved after a dichot-
omy of the data according to the patient’ss e x .N o
signiﬁcant correlations were obtained for the different
variables assayed with the speciﬁc oxidase activity of
ceruloplasmin or the copper/immunoreactive cerulo-
plasmin ratio, which have a signiﬁcant correlation
coefﬁcient between them (r = 0.550; P < 0.001).
In our study, thrombocytopenia was deﬁned as a
plateletcountoflessthan15010
9/L,and11patients
(10 in monotherapy and 1 in polytherapy ) had
thrombocytopenia, with a platelet count of 115 ±
9.7  10
9/L (range 42–146  10
9/L), MPV of
9.5 ± 0.4 fL (range 7.6–11.5 fL), and PDW of
54.8 ± 2.4% (range 39.8%–63.8%). In accordance
with previously published data on the discrimination
of hypo-productive or hyper-destructive thrombocy-
topenia using MPV and PDW platelet indices
(26,27), the decreased platelet count may be due to
a hyper-destruction of peripheral blood platelets in
these patients. Furthermore, in the ﬁve patients (three
in monotherapy and two in polytherapy) with a plate-
let count greater than 400  10
9/L, the calculation of
the residual PDW according to Osselaer et al. (28)
suggests that the discrete thrombocytosis of 491.8 ±
37.7  10
9/L (range 409–601  10
9/L) was secondary
or reactive. No signiﬁcant correlations of the platelet
count with the daily dose or serum levels of VPA were
found.
Figure 1 shows the distribution of the values
obtained for the APRI and FIB-4 liver ﬁbrosis indices
in 50 healthy controls and the patients who were
studied. The correlation coefﬁcient of the APRI index
with the platelet count was r = –0.764 (P < 0.001), and
with AST activity r = 0.635 (P < 0.001). The corre-
lation of FIB-4 score with platelet count (r = –0.606;
P < 0.001) was also greater than with AST (r = 0.348;
P < 0.005). The ﬁrst-order partial correlation coefﬁ-
cient of the APRI index with platelet count (main-
taining AST as a constant) was r = –0.898 (P < 0.001),
and with AST activity (maintaining platelet count as a
constant) r = 0.849 (P < 0.001). The partial correla-
tions of the FIB-4 score with the platelet count
was r = –0.607 (P < 0.001), and with AST
r = 0.350 (P < 0.005).
Discussion
It has been previously described that non-alcoholic
fatty liver disease is present in 61% of the patients
Table I. Results obtained in the patients treated with valproic acid in monotherapy according to its ceruloplasmin-speciﬁc oxidase activity.
Speciﬁc oxidase activity <333(U/g) Speciﬁc oxidase activity ‡333(U/g)
n (males/females) 28 (18/10) 47 (21/26)
VPA Css (mg/L) 63.2 ± 4.0 (67.9) 63.5 ± 2.7 (60.4)
VPA dose (mg/24h) 1170.0 ± 93.1 (1200.0) 1241.9 ± 86.1 (1000.0)
Speciﬁc oxidase activity (U/g) 278.5 ± 6.8 (276.1)
a 430.5 ± 13.0 (405.4)
Copper/ceruloplasmin ratio (mg/mg) 3.2 ± 0.1 (3.2)
a 3.9 ± 0.1 (3.8)
Glucose (mg/dL) 94.5 ± 5.1 (89.0) 88.4 ± 2.0 (87.5)
Cholesterol (mg/dL) 191.0 ± 10.2 (199.0) 175.5 ± 8.2 (171.0)
Triglycerides (mg/dL) 134.5 ± 13.2 (108.0) 107.7 ± 8.9 (99.0)
GGT (U/L) 31.6 ± 8.8 (12.6) 17.2 ± 2.5 (10.0)
ALP (U/L) 161.2 ± 11.3 (132.0) 162.1 ± 3.7 (143.0)
ChE (U/L) 7061.6 ± 407.4 (7250.0) 7005.9 ± 229.4 (7050.0)
AST(U/L) 14.6 ± 1.1 (13.5) 16.7 ± 1.9 (13.0)
ALT(U/L) 19.2 ± 1.6 (20.0) 22.1 ± 3.9 (14.5)
AST/ALT ratio 0.8 ± 0.1 (0.8) 0.9 ± 0.1 (0.7)
CRP (mg/L) 3.4 ± 1.2 (1.4) 6.6 ± 2.6 (1.4)
APRI score 0.37 ± 0.06(0.30) 0.35 ± 0.05(0.30)
FIB-4 score 0.89 ± 0.12(0.80) 0.84 ± 0.12(0.60)
aSigniﬁcance: P < 0.01.
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patients may have a diminished copper availability
(11), a particular condition that would be involved in
the development of liver steatosis (12–14). A relevant
proportion of non-alcoholic fatty liver disease patients
had low copper stores (12,13), which is associated
with more pronounced insulin resistance and other
clinicalfeatures of the metabolicsyndrome, and might
be a typical feature of pathophysiological relevance to
its hepatic manifestation as non-alcoholic fatty liver
disease (12,13). Patients with serum copper levels in
the currently applied ‘normal’ range may include a
signiﬁcant proportion of cases with copper stores that
can be considered depleted (12).
The speciﬁc oxidase activity of circulating cerulo-
plasmin, which in adults is not inﬂuenced by non-
dietary factors such as age, gender, or hormone use, is
a more sensitive indicator of copper status than either
serum copper, ceruloplasmin, or erythrocyte super-
oxide dismutase (29,30). In the VPA-treated patients
with ceruloplasmin-speciﬁc oxidase activity below
the lower limit of reference (333 U/L) a reduced
copper content of the circulating ceruloplasmin due
to the diminished liver copper availability should be
supposed (11).
Recently, it has been reported that the severity
of non-alcoholic fatty liver disease correlates with
high-sensitivity CRP values (31). In our patients, a
signiﬁcant relationship of the speciﬁc oxidase activity
of ceruloplasmin with CRP levels was not attained,
indicating that the speciﬁc oxidase activity is not
inﬂuenced by the inﬂammatory status. Signiﬁcant
increases of the serum AST, ALT, GGT, and ChE
activities in groups of patients with non-alcoholic fatty
liver disease are well documented (15–22), as well as
its correlation with the grade of steatosis and ﬁbrosis
assessed by liver ultrasound (17,19,20). In particular,
increased serum ChE is considered a useful marker of
liver steatosis (21,32), associated with adiposity, insu-
lin resistance, lipid proﬁle (22,33), and fatty liver
inﬁltration degree (34). The serum levels of AST,
ALT, GGT, and ChE, and AST/ALT ratio, APRI
and FIB-4 indices were analogous and without sig-
niﬁcant differences between the groups of VPA-
treated patients with ceruloplasmin-speciﬁc oxidase
activities lower or greater than 333 U/L (Tables I
and II). These results do not conﬁrm the hypothesis of
a signiﬁcant association between copper deﬁciency
and fatty liver disease in the patients treated
with VPA.
It has been hypothesized that elevated ChE
activities could lead to a decrease of acetyl-
choline which has anti-inﬂammatory actions and
consequently could trigger the onset of low-grade
Table II. Results obtained in the patients treated with valproic acid in polytherapy according to its ceruloplasmin-speciﬁc oxidase activity.
Speciﬁc oxidase activity<333(U/g) Speciﬁc oxidase activity ‡333(U/g)
n (males/females) 10 (7/3) 16 (10/6)
VPA Css (mg/L) 49.4 ± 4.1 (48.1) 49.1 ± 6.3 (41.5)
VPA dose (mg/24h) 1900.0 ± 362.5 (1500.0) 1733.3 ± 244.5 (1500.0)
Speciﬁc oxidase activity (U/g) 256.0 ± 19.5 (279.8)
b 454.3 ± 18.0 (439.3)
Copper/ceruloplasmin ratio (mg/mg) 3.3 ± 0.2 (3.2)
a 3.9 ± 0.2 (3.9)
Glucose (mg/dL) 85.4 ± 1.7 (86.0) 98.9 ± 7.8(87.5)
Cholesterol (mg/dL) 215.4 ± 19.6 (194.0) 222.8 ± 23.5 (209.0)
Triglycerides (mg/dL) 126.8 ± 17.6 (130.5) 130.2 ± 25.0 (102.0)
GGT (U/L) 65.0 ± 19.3 (50.5) 70.6 ± 18.2 (44.0)
ALP (U/L) 145.2 ± 21.1 (147.0) 201.2 ± 34.1 (164.5)
ChE (U/L) 7198.6 ± 845.9 (7308.0) 7638.0 ± 798.0 (7147.0)
AST(U/L) 17.6 ± 4.4 (14.5) 15.9 ± 1.7 (15.0)
ALT(U/L) 27.4 ± 9.2 (19.0) 21.1 ± 3.1 (16.0)
AST/ALT ratio 0.8 ± 0.1 (0.7) 0.9 ± 0.1 (0.8)
CRP (mg/L) 38.7 ± 26.0 (8.9) 27.0 ± 14.7 (4.9)
APRI score 0.33 ± 0.07(0.30) 0.25 ± 0.04 (0.20)
FIB-4 score 0.69 ± 0.12(0.70) 0.63 ± 0.15 (0.50)
aSigniﬁcance: P < 0.05.
bSigniﬁcance: P < 0.001.
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of serum ChE (37,38) and CRP (39,40) have been
reported in epileptic patients treated with different
anticonvulsant drugs. In our patients having CRP
concentrations lower than 10 mg/L (subclinical
chronic inﬂammation), a signiﬁcant positive corre-
lation between serum ChE and CRP was found
(r = 0.410;P < 0.001); however, in the cases with
CRP greater than 10 mg/L (acute inﬂammation
conditions) the correlation coefﬁcient between these
two variables was negative, although due to the low
number of patients considered, statistical signiﬁ-
cance was not achieved (r = –0.405;P = 0.084).
Similarly, in the group of patients with CRP levels
lower than 10 mg/L the ChE activity was signiﬁ-
cantly higher (P < 0.005) than in the patients with
CRP greater than 10 mg/L (7,400.9 ± 189.7 U/L
(7,309.0 U/L) versus 5,846.5 ± 681.2 U/L
(6,004.0 U/L)), possibly due to a greater liver injury
in these last patients. This is an interesting subject
that should be studied in a greater detail.
Non-alcoholic fatty liver disease ranges from simple
steatosis, with a benign course, to non-alcoholic
steatohepatitis with necroinﬂammation and ﬁbrosis,
which can progress to cryptogenic cirrhosis and end-
stage liver disease. As shown in Figure 1, most control
subjects (98%) and VPA-treated patients (93%) have
low scores for the APRI (<0.5) and FIB-4 (<1.45)
indices, suggesting the absence of liver ﬁbrosis in
these cases. Likewise, in the remaining patients the
values obtained for both indices suggest a low likeli-
hood of signiﬁcant hepatic ﬁbrosis. Only a 95-year-
old male patient with platelet count of 107  10
9/L,
AST 16 U/L, and ALT 11 U/L (AST/ALT
ratio = 1.45), and presenting low serum levels of
GGT 12 U/L, ChE 4,621 U/L, and albumin
31 g/L, had a FIB-4 score of 4.3 indicative of severe
liver ﬁbrosis, although the APRI index was 0.60.
The variables AST activity and platelet count are
used for the calculation of the APRI (24) and
FIB-4 (25) liver ﬁbrosis indices. With the progression
of liver ﬁbrosis, serum AST activity increases due to
its release from mitochondria and its diminished
clearance; likewise, the platelet count decreases due
to a hypo-production of thrombopoietin by the hepa-
tocytes and an increased circulating platelet destruc-
tion in spleen, as portal hypertension develops. In the
VPA-treated patients studied, the coefﬁcient of deter-
mination (estimated from the correspondent ﬁrst
partial correlation coefﬁcients indicated above) shows
that the APRI score is slightly more dependent on
the platelet count (r
2 = 0.806) than AST activity
(r
2 = 0.721). The dependence of FIB-4 score on
the platelet count (r
2 = 0.368) was also higher than
with AST activity (r
2 = 0.122).
Considering the MPV and PDW platelet indices of
our 11 patients with thrombocytopenia, this fact may
be due to a hyper-destruction of the circulating
platelets as was indicated above. Thrombocytopenia
is the most common hematologic adverse effect of
VPA, although the exact mechanism has not yet been
elucidated (41). Our study did not reveal any signif-
icant correlation between serum VPA concentration
and platelet count, or signiﬁcant higher VPA
levels in the 11 patients with platelet count lower
than 150  10
9/L with respect to the remaining
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Figure1. Distribution ofthe APRIscore(A)and FIB-4score(B)in
males (.) and females (*) controls and patients treated with
valproic acid in monotherapy (VPAM) and polytherapy (VPAP).
The dashed lines correspond to the cut-off values for absence
(APRI <0.5; FIB-4 <1.45) or presence of signiﬁcant liver ﬁbrosis
(APRI>1.5; FIB-4 >3.25).
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bocytopenia in these cases was not mediated by direct
drug toxicity on the blood platelets. However, a VPA-
induced formation of autoantibodies against platelets
is possible (41), and the results obtained for the MPV
and PDW indices in our patients are compatible with
a hyper-destruction or reduced circulating platelet
survival, similar to that seen in immune thrombocy-
topenia. If this assumption is correct, the APRI and
FIB-4 scores would be falsely increased, at least in
some cases, reinforcing the suggestion expressed
above that in the studied group of VPA-treated
patients there is no signiﬁcant liver ﬁbrosis. With
regard to these results, the recently described in-vitro
and in-vivo inhibitory effect of VPA on the hepatic
stellate cell activation, and consequently on ﬁbrosis
development in chronically injured mouse liver (42),
should be considered.
Unfortunately a diagnosis of non-alcoholic fatty
liver disease by ultrasonography was not carried out
in our study. In any case, the results we have obtained
suggest that the decreased copper availability present
in the epileptic patients treated with VPA is not
associated with fatty liver disease. Copper status is
linked to iron homeostasis, and copper deﬁciency
causes hepatic iron accumulation that is frequently
associated with hepatic steatosis (12). Increased liver
iron can promote oxidative stress and insulin resis-
tance; however, these processes may be modulated by
haptoglobin polymorphism, and Hp2-2 phenotype
would be a risk factor for metabolic syndrome and
non-alcoholic fatty liver disease (43). The association
between copper availability, iron metabolism, hapto-
globin polymorphism, and metabolic syndrome
requires clariﬁcation.
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